STMN1 and neoplasm: In view of the anti-metastatic effect of Rh2E2 in vivo (Figure 3A), proteomic profiling provided evidence that several tumor metastatic markers, such as α-enolase, stathmin, cofilin-1, Rho GDP-dissociation inhibitor 1 and thromboxane-A synthase [31–34, 40], probably participate in the anti-metastatic actions of Rh2E2.